Naratuximab emtansine is a new ADC therapy for patients with B-cell malignancies working by delivering a potent cytotoxic via a novel disease target, CD37. The potential benefit observed with this potent ADC technology have brought us to the stage of actively seeking a global partner to unfold the full value of this novel therapeutic option.